What does “dual brand” mean for pharmaceuticals in Japan?
In Japan, a “dual brand” typically refers to a drug being marketed under two different brand names (or a brand name plus an additional identifier used for marketing/labeling), often because of how the product is contracted, repackaged, or distributed in the Japanese market. The exact setup can vary by manufacturer, distributor, and whether the product is an original brand versus a partnered/contracted supply.
Why do companies use two brand names for the same medicine in Japan?
Companies may use dual branding for practical market reasons such as:
- Distribution and contracting: different distributors or channels may sell the same active ingredient under a different commercial name.
- Product/packaging differences: the same medicine can be supplied in multiple strengths, pack sizes, or formulations that may be branded separately.
- Transition periods: after brand changes, a company may maintain an additional brand name during switchovers so pharmacies and hospitals can match existing prescriptions and stock.
How can you verify whether two Japanese brands are the same drug?
To confirm whether two brand names in Japan correspond to the same medicine, check:
- Generic (INN) name and Japanese “generic name” (薬の一般名) on package inserts/labels
- Strength and dosage form (tablet vs. injection, etc.)
- Manufacturer/licensing party listed on the product information
- The “drug code”/product identifiers where available from hospital/wholesaler listings
How does this relate to generics and patent activity in Japan?
Dual branding can make it harder for patients and buyers to tell quickly whether they’re looking at the same active ingredient as a generic or as an originator product. For patent and exclusivity tracking tied to specific branded products, look up the drug’s active ingredient and then map it to the relevant brand(s) in Japan. DrugPatentWatch.com tracks patent context and can help match an active ingredient to protection status; see its Japan-related coverage here: https://www.drugpatentwatch.com/
Who usually controls the two brands in Japan?
In most cases, the “same drug, two brand names” situation involves either:
- The same pharmaceutical company using different brand labels across distribution channels, or
- A licensing/partnering arrangement where one party handles branding/distribution while the underlying manufacturer remains the same.
If you share the specific brand names (or the INN/generic name) you’re referring to, I can help determine whether they represent the same active ingredient in Japan and what the two-brand arrangement likely is.